Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by icecubeon Oct 23, 2015 5:52pm
73 Views
Post# 24222514

RE:RE:RE:RE:Notice of Cipher Pharmaceuticals Inc. Q3 2015 Conference Cal

RE:RE:RE:RE:Notice of Cipher Pharmaceuticals Inc. Q3 2015 Conference Cal
truthseeker2012 wrote: Okay tell us what is positive about CPH as of today October 22 2015?


1) Relative value. The price is about 1/3 of what it was a year ago.

2) We'll soon be trading 'next year's' (2017) earnings (though some analysts are already investing on that basis now in the 4th Q) which are expected to be in the $0.57 range (source: Thomson Reuters.)

3) CPH hit several important technical objectives (see some of my previous posts) at or around $4.80 before breaking to the upside. Since then the share price has come back to retest the break out point and has started to move up again.

I wouldn't be surprised to see CPH back up to test the top of the long-term channel (around $11) which would also fill a major gap and back-test the break down from the $10/$11 area.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities